Immunitas Therapeutics

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
CD161 (KLRB1)Monoclonal antibody
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 April 2026PresentationRezorstobartPhase 1/2a IMT-009 (NCT05565417) data at AACR 2026: early anti-tumour activity in heavily pretreated patients

Financial reports

No financial reports recorded.